Cell therapy stimulates bone neoformation in calvaria defects in rats subjected to local irradiation.
calvaria
cell therapy
irradiation
osteoblasts
rats
Journal
Animal models and experimental medicine
ISSN: 2576-2095
Titre abrégé: Animal Model Exp Med
Pays: United States
ID NLM: 101726292
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
11
02
2019
revised:
02
05
2019
accepted:
31
05
2019
entrez:
28
11
2019
pubmed:
28
11
2019
medline:
28
11
2019
Statut:
epublish
Résumé
The purpose of the study was to analyze the effect of cell therapy on the repair process in calvaria defects in rats subjected to irradiation. Bone marrow mesenchymal cells were characterized for osteoblastic phenotype. Calvariae of male Wistar rats were irradiated (20 Gy) and, after 4 weeks, osteoblastic cells were placed in surgically created defects in irradiated (IRC) and control animals (CC), paired with untreated irradiated (IR) and control (C) animals. After 30 days, histological and microtomographic evaluation was performed to establish significant ( Higher alkaline phosphatase detection and activity, along with an increase in mineralized nodules, in the IRC, C and CC groups compared to the IR group, confirmed an osteoblastic phenotype. Histology showed impaired bone neoformation following irradiation, affecting bone marrow composition. Cell therapy in the IRC group improved bone neoformation compared to the IR group. Microtomography revealed increased bone volume, bone surface and trabecular number in IRC group compared to the IR group. Cell therapy may improve bone neoformation in defects created after irradiation.
Sections du résumé
BACKGROUND
BACKGROUND
The purpose of the study was to analyze the effect of cell therapy on the repair process in calvaria defects in rats subjected to irradiation.
METHODS
METHODS
Bone marrow mesenchymal cells were characterized for osteoblastic phenotype. Calvariae of male Wistar rats were irradiated (20 Gy) and, after 4 weeks, osteoblastic cells were placed in surgically created defects in irradiated (IRC) and control animals (CC), paired with untreated irradiated (IR) and control (C) animals. After 30 days, histological and microtomographic evaluation was performed to establish significant (
RESULTS
RESULTS
Higher alkaline phosphatase detection and activity, along with an increase in mineralized nodules, in the IRC, C and CC groups compared to the IR group, confirmed an osteoblastic phenotype. Histology showed impaired bone neoformation following irradiation, affecting bone marrow composition. Cell therapy in the IRC group improved bone neoformation compared to the IR group. Microtomography revealed increased bone volume, bone surface and trabecular number in IRC group compared to the IR group.
CONCLUSION
CONCLUSIONS
Cell therapy may improve bone neoformation in defects created after irradiation.
Identifiants
pubmed: 31773092
doi: 10.1002/ame2.12073
pii: AME212073
pmc: PMC6762041
doi:
Types de publication
Journal Article
Langues
eng
Pagination
169-177Informations de copyright
© 2019 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
Déclaration de conflit d'intérêts
None.
Références
Yonsei Med J. 2016 Jul;57(4):1006-15
pubmed: 27189298
J Oral Maxillofac Surg. 1983 May;41(5):283-8
pubmed: 6572704
Radiother Oncol. 2004 Nov;73(2):119-31
pubmed: 15542158
Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii73-8
pubmed: 14532155
Ann Maxillofac Surg. 2014 Jul-Dec;4(2):189-92
pubmed: 25593871
Head Face Med. 2011 Feb 18;7:5
pubmed: 21332971
Otolaryngol Head Neck Surg. 2017 Apr;156(4):616-621
pubmed: 28116973
Crit Rev Oral Biol Med. 2003;14(3):213-25
pubmed: 12799324
Regen Med. 2015;10(2):127-33
pubmed: 25835478
Anal Biochem. 2004 Jun 1;329(1):77-84
pubmed: 15136169
Animal Model Exp Med. 2019 Jul 01;2(3):169-177
pubmed: 31773092
Oral Oncol. 2010 Nov;46(11):795-801
pubmed: 20843728
J Dent Res. 2012 Jul;91(7):702-8
pubmed: 22592127
J Cell Biol. 1999 Jan 11;144(1):161-73
pubmed: 9885252
J Oral Maxillofac Surg. 1997 Jun;55(6):540-4; discussion 545-6
pubmed: 9191633
Am J Phys Anthropol. 2007 Aug;133(4):1099-111
pubmed: 17530700
Cytokine. 2000 Nov;12(11):1630-8
pubmed: 11052813
Oral Maxillofac Surg Clin North Am. 2011 Aug;23(3):455-64
pubmed: 21798443
J Mater Sci Mater Med. 2016 Dec;27(12):180
pubmed: 27770393
Eur J Prosthodont Restor Dent. 2013 Jun;21(2):80-7
pubmed: 23888531
J Craniomaxillofac Surg. 2015 Oct;43(8):1478-86
pubmed: 26220883
J Bone Miner Res. 2010 Jul;25(7):1668-79
pubmed: 20200952
Br J Oral Maxillofac Surg. 2009 Dec;47(8):602-7
pubmed: 19200627
Otolaryngol Head Neck Surg. 2011 Sep;145(3):404-10
pubmed: 21493310
Head Neck. 2016 Sep;38(9):1428-35
pubmed: 27453348
J Oral Surg. 1970 Jan;28(1):17-26
pubmed: 5262227
J Bone Miner Res. 1987 Dec;2(6):595-610
pubmed: 3455637
Crit Rev Oncol Hematol. 2016 Nov;107:39-43
pubmed: 27823650
Tissue Eng Part A. 2012 May;18(9-10):999-1005
pubmed: 22150110
J Craniomaxillofac Surg. 2015 Nov;43(9):1829-36
pubmed: 26433771
Tissue Eng Part A. 2012 Sep;18(17-18):1902-11
pubmed: 22721548
Oral Maxillofac Surg. 2010 Mar;14(1):3-16
pubmed: 20119841
Haematologica. 2003 Aug;88(8):845-52
pubmed: 12935972
J Oral Maxillofac Surg. 2016 Jan;74(1):190-9
pubmed: 26253013
Plast Reconstr Surg. 2015 Mar;135(3):799-806
pubmed: 25415276
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1084-91
pubmed: 19327914
Hum Gene Ther. 2011 Jan;22(1):19-26
pubmed: 21028982
Cytotechnology. 2013 Mar;65(2):223-31
pubmed: 22806484
J Craniofac Surg. 1998 Jul;9(4):310-6
pubmed: 9780924